In contrast to the poor outcomes reported in the EGFR mutation group, the pCR rate of 26% in our no-driver group was consistent with the rate of pCR reported in several large retrospective trials evaluating pathologic response following NA-ChRT in resectable LA-NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.